TMCnet News
PaxVax Presents Positive Efficacy Results for Phase 3 Cholera Challenge Study [Professional Services Close - Up](Professional Services Close - Up Via Acquire Media NewsEdge) PaxVax has reported positive efficacy results from the 90-day challenge studies of its single-dose oral cholera vaccine candidate, PXVX0200, which utilizes the same attenuated vaccine strain (CVD 103- HgR) previously approved and marketed in several countries under the brand name Orochol. In its release, the Company said that trial investigators compared the rate of diarrhea in participants vaccinated with PXVX0200 to the rate in participants who had received placebo. Vaccine efficacy was evaluated by immunizing volunteer participants with an oral dose of the PXVX0200 vaccine or placebo and then subsequently exposing them to the cholera-causing agent (Vibrio cholerae O1 El Tor). Volunteer participants in this challenge study were divided into two groups - the first group was vaccinated and then challenged at 10 days after vaccination, and a second, separate group of volunteer participants was challenged at 90 days post vaccination to further evaluate duration of vaccine protection. In an analysis of participants challenged at 90 days post vaccination with wild type, fully pathogenic cholera bacteria, the efficacy rate was 79.5 percent - four of 33 participants who received PXVX0200 experienced moderate-to-severe diarrhea compared to 39 of 66 participants who received placebo. In the 10-day study group, post vaccination with wild type, fully pathogenic cholera bacteria, the efficacy rate was 90.3 percent - two of 35 participants who received PXVX0200 experienced moderate-to-severe diarrhea compared to 39 of 66 participants who received placebo. Study Investigator Beth Kirkpatrick, M.D., Professor of Medicine, Infectious Disease Medicine, Department of Medicine, University of Vermont said: "The 90-day challenge results are very encouraging and provide important new data that further support the efficacy of PXVX0200 in protecting people exposed to cholera. If approved, PXVX0200 has the potential to provide an effective new single-dose option for people living in and travelling to areas where cholera is endemic." In addition to the 10- and 90-day cholera challenge studies, immunogenicity, safety, and lot-to-lot consistency of the PXVX0200 cholera vaccine are being evaluated in a broader population at study sites in Australia, Canada, and the U.S. Approximately 3,000 participants are being enrolled in these additional pivotal Phase 3 clinical studies. "These favorable data build on a successful 10-day challenge study and provide important new data to support a Biologics License Application for PXVX0200, our lead commercial vaccine candidate," said Kenneth Kelley, Chief Executive Officer of PaxVax. "U.S. travelers currently have limited options to protect themselves from cholera, and we are pleased with the progress we are making in bringing an effective and logistically simple, single-dose cholera vaccine to travelers as well as developing countries for use during fast-moving cholera outbreaks." PaxVax is a specialty vaccine company focused on developing effective vaccines for travel and biodefense. More Information and Complete Details: www.PaxVax.com ((Comments on this story may be sent to [email protected])) (c) 2014 ProQuest Information and Learning Company; All Rights Reserved. |